The FDA has approved the first messenger RNA (mRNA) flu vaccine for older adults, offering a new protection option ahead of the upcoming flu season. The vaccine, developed using the same technology behind COVID-19 shots, represents a significant advance in immunization strategy for people aged 60 and older.
mRNA vaccines work by instructing cells to produce a harmless piece of the flu virus protein, triggering an immune response without exposing people to the actual virus. This approach differs from traditional flu vaccines, which rely on either inactivated virus or egg-based production methods. The new technology allows for faster development and can be updated quickly if flu strains change.
Older adults face higher risks during flu season. People over 65 account for a substantial portion of flu hospitalizations and deaths annually, according to CDC data. Traditional flu vaccines offer variable protection in this age group, sometimes ranging from 40 to 60 percent effectiveness, depending on the season and vaccine strain match.
The approval follows clinical trials demonstrating the mRNA vaccine's ability to generate robust immune responses in older adults. Researchers found the new vaccine produced stronger antibody responses compared to standard flu vaccines in this population. The vaccine was well tolerated, with side effects similar to conventional flu shots.
Healthcare providers can now offer older patients another vaccination option. Some adults may choose the mRNA vaccine, while others may prefer traditional formulations. The availability of multiple vaccine types gives older adults and their doctors flexibility in choosing the approach that works best for their individual health situations.
Timing matters for flu protection. Health experts recommend getting vaccinated by the end of October to ensure immunity develops before flu activity peaks in winter months. Older adults should discuss vaccination options with their healthcare providers to determine which vaccine best suits their medical history and needs.